Bristol-Myers Squibb Co., one of the nation’s biggest drugmakers, said Thursday that its third-quarter earnings plunged 65% because two key drugs struggled with generic competition and results a year ago were swelled by a one-time gain. It also raised earnings guidance for the year and said one of the government investigations into a patent deal has been expanded.
*For more on this story,
read the full AP article.
